S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Avadel Pharmaceuticals Stock Forecast, Price & News

+0.06 (+0.91 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $6.67
50-Day Range
MA: $6.96
52-Week Range
Now: $6.67
Volume270,792 shs
Average Volume442,183 shs
Market Capitalization$388.66 million
P/E Ratio33.35
Dividend YieldN/A
Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Avadel Pharmaceuticals logo


Overall MarketRank

1.35 out of 5 stars

Medical Sector

544th out of 1,558 stocks

Pharmaceutical Preparations Industry

276th out of 638 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AVDL



Sales & Book Value

Annual Sales$59.22 million
Book Value($0.78) per share


Net Income$-33,230,000.00


Market Cap$388.66 million
Next Earnings Date3/11/2021 (Estimated)
+0.06 (+0.91 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AVDL News and Ratings via Email

Sign-up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions

How has Avadel Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Avadel Pharmaceuticals' stock was trading at $7.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AVDL stock has decreased by 16.5% and is now trading at $6.67.
View which stocks have been most impacted by COVID-19

Is Avadel Pharmaceuticals a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Avadel Pharmaceuticals stock.
View analyst ratings for Avadel Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Avadel Pharmaceuticals?

Wall Street analysts have given Avadel Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Avadel Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Avadel Pharmaceuticals' next earnings date?

Avadel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Avadel Pharmaceuticals

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) issued its earnings results on Saturday, November, 14th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.05. Avadel Pharmaceuticals had a negative return on equity of 33.91% and a net margin of 38.70%.
View Avadel Pharmaceuticals' earnings history

What price target have analysts set for AVDL?

9 analysts have issued 1 year price targets for Avadel Pharmaceuticals' stock. Their forecasts range from $13.50 to $22.00. On average, they expect Avadel Pharmaceuticals' share price to reach $16.56 in the next twelve months. This suggests a possible upside of 148.3% from the stock's current price.
View analysts' price targets for Avadel Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Avadel Pharmaceuticals' key competitors?

What other stocks do shareholders of Avadel Pharmaceuticals own?

Who are Avadel Pharmaceuticals' key executives?

Avadel Pharmaceuticals' management team includes the following people:
  • Mr. Gregory J. Divis Jr., CEO & Director (Age 54, Pay $917.95k)
  • Mr. Thomas S. McHugh, Sr. VP & CFO (Age 56, Pay $404.26k)
  • Dr. Jordan S. Dubow M.D., Consultant (Age 43, Pay $567.63k)
  • Mr. Gregory J. Davis, VP of Corp. and Bus. Devel. (Age 56)
  • Mr. Mark W. Elrod, VP of Sales
  • Mrs. Séverine Martin, Director of HR and Corp. Projects
  • Mr. Christian Kalita Pharm.D, Chief Pharmacist and Director of Quality Assurance & Regulatory Affairs
  • Mr. Steven G. Sullivan, VP of Sales & Marketing and Head of Commercial Operations (Age 56)
  • Dr. Jason M. Vaughn, Sr. VP of Technical Operations
  • Mr. Jerad G. Seurer, VP of Legal Affairs & Corp. Sec.

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $6.67.

How big of a company is Avadel Pharmaceuticals?

Avadel Pharmaceuticals has a market capitalization of $388.66 million and generates $59.22 million in revenue each year. The company earns $-33,230,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Avadel Pharmaceuticals employs 50 workers across the globe.

What is Avadel Pharmaceuticals' official website?

The official website for Avadel Pharmaceuticals is www.avadel.com.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The company can be reached via phone at 011-1-485-1200 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.